Improved allele-specific PCR assays for detection of clarithromycin and fluoroquinolone resistant of Helicobacter pylori in gastric biopsies: Identification of N87I mutation in GyrA

Diagnostic Microbiology and Infectious Disease

Volumn 81, Issue 4, 2015, Pages 251-255

  Trespalacios, Alba A ^a   Rimbara, Emiko ^b,c   Otero, William ^d,e   Reddy, Rita ^b,c   Graham, David Y ^b,c  

^a PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^e Unidad de Gastroenterología Clínica Fundadores   (Colombia)

Author keywords

23S rRNA; Agar dilution; Mutations; Sequencing; SP PCR

Indexed keywords

CLARITHROMYCIN; LEVOFLOXACIN; RNA 23S; ANTIINFECTIVE AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); PRIMER DNA; QUINOLONE DERIVATIVE;

23S RRNA GENE; AGAR DILUTION; ALLELE SPECIFIC POLYMERASE CHAIN REACTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM DETECTION; BACTERIUM ISOLATE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DNA SEQUENCE; GENE MUTATION; GENE SEQUENCE; GENOTYPE; GYRA GENE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STOMACH BIOPSY; UREA GENE; VACA GENE; BIOPSY; CLASSIFICATION; DRUG EFFECTS; EVALUATION STUDY; GASTRIC MUCOSA; GENETICS; HELICOBACTER INFECTIONS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MISSENSE MUTATION; POINT MUTATION; PROCEDURES;

ANTI-BACTERIAL AGENTS; BIOPSY; CLARITHROMYCIN; DNA GYRASE; DNA PRIMERS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MUTATION, MISSENSE; POINT MUTATION; POLYMERASE CHAIN REACTION; RNA, RIBOSOMAL, 23S; SENSITIVITY AND SPECIFICITY;

EID: 84925148708     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2014.12.003     Document Type: Article

References (36)

1. Agudo S., Pérez-Pérez G., Alarcón T., López-Brea M. High prevalence of clarithromycin-resistant Helicobacter pylori strains and risk factors associated with resistance in Madrid, Spain. J Clin Microbiol 2010, 48:3703-3707.
2. Ahmad N., Zakaria W.R., Abdullah S.A., Mohamed R. Characterization of clarithromycin resistance in Malaysian isolates of Helicobacter pylori. World J Gastroenterol 2009, 15:3161-3165.
3. Alfizah H., Norazah A., Hamizah R., Ramelah M. Resistotype of Helicobacter pylori isolates: the impact on eradication outcome. J Med Microbiol 2014, 63(Pt 5):703-709.
4. Ayala G., Chihu L., Perales G., Fierros-Zárate G., Hansen L.M., Solnick J.V., Sánchez J. Quantitation of H. pylori cytotoxin mRNA by real-time RT-PCR shows a wide expression range that does not correlate with promoter sequences. Microb Pathog 2004, 37:163-167.
5. Cambau E., Allerheiligen V., Coulon C., Corbel C., Lascols C., Deforges L., et al. Evaluation of a new test, GenoType HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori. J Clin Microbiol 2009, 47:3600-3607.
6. Cattoir V., Nectoux J., Lascols C., Deforges L., Delchier J.C., Megraud F., et al. Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility. Int J Antimicrob Agents 2007, 29:389-396.
7. Chisholm S.A., Owen R.J., Teare E.L., Saverymuttu S. PCR-based diagnosis of Helicobacter pylori infection and real-time determination of clarithromycin resistance directly from human gastric biopsy samples. J Clin Microbiol 2001, 39:1217-1220.
8. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing; twentieth informational supplement: M100-S20 2010, CLSI, Wayne, PA,USA.
9. De Francesco V., Zullo A., Giorgio F., Saracino I., Zaccaro C., Hassan C., et al. Change of point mutations in Helicobacter pylori rRNA associated with clarithromycin resistance in Italy. J Med Microbiol 2014, 63(Pt 3):453-457.
10. Clinical breakpoints for Helicobacter pylori Available from:. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Consultation/EUCAST_clinical_breakpoints_for_Helicobacter_pylori.pdf.
11. Fontana C., Favaro M., Minelli S., Criscuolo A.A., Pietroiusti A., Galante A., et al. New site of modification of 23S rRNA associated with clarithromycin resistance of Helicobacter pylori clinical isolates. Antimicrob Agents Chemother 2002, 46:3765-3769.
12. Furuta T., Graham D.Y. Pharmacologic aspects of eradication therapy for Helicobacter pylori infection. Gastroenterol Clin N Am 2010, 39:465-480.
13. Furuta T., Soya Y., Sugimoto M., Shirai N., Nakamura A., Kodaira C., et al. Modified allele-specific primer-polymerase chain reaction method for analysis of susceptibility of Helicobacter pylori strains to clarithromycin. J Gastroenterol Hepatol 2007, 22:1810-1815.
14. Garrido L., Toledo H. Novel genotypes in Helicobacter pylori involving domain V of the 23S rRNA gene. Helicobacter 2007, 12:505-509.
15. Graham D.Y. Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin Gastroenterol Hepatol 2009, 7:145-148.
16. Heo J., Jeon S.W. Optimal treatment strategy for Helicobacter pylori: era of antibiotic resistance. World J Gastroenterol 2014, 20(19):5654-5659.
17. Ho S.L., Tan E.L., Sam C.K., Goh K.L. Clarithromycin resistance and point mutations in the 23S rRNA gene in Helicobacter pylori isolates from Malaysia. J Dig Dis 2010, 11:101-105.
18. Hung K.H., Sheu B.S., Chang W.L., Wu H.M., Liu C.C., Wu J.J. Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a university hospital in Southern Taiwan. Helicobacter 2009, 14:61-65.
19. Kim K.S., Kang J.O., Eun C.S., Han D.S., Choi T.Y. Mutations in the 23S rRNA gene of Helicobacter pylori associated with clarithromycin resistance. J Korean Med Sci 2002, 17:599-603.
20. Kist M. Isolation and identification of bacteria of the genera Campylobacter and Helicobacter. Zentralbl Bakteriol 1991, 276:124-139.
21. Lehours P., Siffré E., Mégraud F. DPO multiplex PCR as an alternative to culture and susceptibility testing to detect Helicobacter pylori and its resistance to clarithromycin. BMC Gastroenterol 2011, 11:112.
22. Malfertheiner P., Megraud F., O'Morain C.A., Atherton J., Axon A.T., Bazzoli F., et al. Management of Helicobacter pylori infection--the Maastricht IV/Florence Consensus Report. Gut 2012, 61(5):646-664.
23. Marais A., Monteiro L., Occhialini A., Pina M., Lamouliatte H., Mégraud F. Direct detection of Helicobacter pylori resistance to macrolides by a polymerase chain reaction/DNA enzyme immunoassay in gastric biopsy specimens. Gut 1999, 44(4):463-467.
24. Miyachi H., Miki I., Aoyama N., Shirasaka D., Matsumoto Y., Toyoda M., et al. Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan. Helicobacter 2006, 11:243-249.
25. Nakamura A., Furuta T., Shirai N., Sugimoto M., Kajimura M., Soya Y., et al. Determination of mutations of the 23S rRNA gene of Helicobacter pylori by allele specific primer-polymerase chain reaction method. J Gastroenterol Hepatol 2007, 22:1057-1063.
26. Nishizawa T., Suzuki H., Umezawa A., Muraoka H., Iwasaki E., Masaoka T., et al. Rapid detection of point mutations conferring resistance to fluoroquinolone in gyrA of Helicobacter pylori by allele-specific PCR. J Clin Microbiol 2007, 45:303-305.
27. Papastergiou V., Georgopoulos S.D., Karatapanis S. Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance. World J Gastroenterol 2014, 20(29):9898-9911.
28. Riddle D.L., Stratford P.W. Interpreting validity indexes for diagnostic tests: an illustration using the Berg balance test. Phys Ther 1999, 79:939-948.
29. Rimbara E., Noguchi N., Kawai T., Sasatsu M. Novel mutation in 23S rRNA that confers low-level resistance to clarithromycin in Helicobacter pylori. Antimicrob Agents Chemother 2008, 52:3465-3466.
30. Sugimoto M., Uotani T., Sahara S., Ichikawa H., Yamade M., Sugimoto K., et al. Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. Helicobacter 2014, 19(4):312-318.
31. Taylor D.E., Ge Z., Purych D., Lo T., Hiratsuka K. Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. Antimicrobial Agents and Chemotherapy 1997, 41:2621-2628.
32. van Doorn L.J., Glupczynski Y., Kusters J.G., Mégraud F., Midolo P., Maggi-Solcà N., et al. Accurate prediction of macrolide resistance in Helicobacter pylori by a PCR line probe assay for detection of mutations in the 23S rRNA gene: multicenter validation study. Antimicrob Agents Chemother 2001, 45:1500-1504.
33. Wang G., Sayeedur M., Humayun Z., Taylor D. Multiplex sequence analysis demonstrates the competitive growth advantage of the A-to-G mutants of clarithromycin-resistant Helicobacter pylori. Antimicrob Agents Chemother 1999, 43:683-685.
34. Wang G., Wilson T.J., Jiang Q., Taylor D.E. Spontaneous mutations that confer antibiotic resistance in Helicobacter pylori. Antimicrob Agents Chemother 2001, 45(3):727-733.
35. Wang L.H., Cheng H., Hu F.L., Li J. Distribution of gyrA mutations in fluoroquinolone-resistant Helicobacter pylori strains. World J Gastroenterol 2010, 16:2272-2277.
36. Xiong L.J., Tong Y., Wang Z., Mao M. Detection of clarithromycin-resistant Helicobacter pylori by stool PCR in children: a comprehensive review of literature. Helicobacter 2013, 18(2):89-101.